i
CDC trials : pre-exposure prophylaxis for HIV prevention
-
February 2011
-
Source: CDC fact sheet
[PDF-615.54 KB]
Details:
-
Alternative Title:Pre-exposure prophylaxis for HIV prevention
-
Corporate Authors:
-
Description:New tools to prevent HIV are urgently needed to stem the estimated 2.6 million new HIV infections that occur worldwide each year. Recent research has shown that a new approach called pre-exposure prophylaxis, or PrEP, can reduce the risk of contracting HIV in gay and bisexual men at high risk of infection, when combined with existing prevention measures. Ongoing studies are evaluating this approach in other populations at risk for HIV, including heterosexuals and injection drug users.
In this new approach to HIV prevention, people who are uninfected take an HIV treatment pill daily to reduce their risk of becoming infected. By inhibiting HIV from replicating as it enters the body, PrEP can prevent the virus from establishing permanent infection. The concept of providing a preventative treatment before exposure to an infectious agent is not new. For example, when individuals travel to an area where malaria is common, they are advised to take malaria treatment medication before and during travel to prevent illness.
As part of its commitment to developing new HIV prevention strategies, the Centers for Disease Control and Prevention has sponsored several clinical trials to evaluate the safety and efficacy of PrEP for HIV prevention.
-
Subjects:
-
Source:
-
Document Type:
-
Genre:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
